Offerings include new Stax™ single-use systems and filtration technologies
FRANKFURT, Germany (May 12, 2009) -- Biotechnology is considered one of the key technologies that will enable the long-term sustainable development of the European Union in terms of economic growth, environmental protection, and public health. To remain competitive in today’s worldwide economic climate, European biotechnology firms must continue to increase their speed and capacity for conducting research, generating new knowledge, and converting it into new products and processes.
At ACHEMA 2009, Pall Corporation (NYSE: PLL) will help Europe’s biotechnology and biopharmaceutical industries meet their demanding research, development and production needs with its new filtration technologies and single-use systems. By leveraging these technologies, Pall’s customers can stimulate research and promote the delivery of industry innovations in order to advance Europe’s contributions to the worldwide biotechnology and pharmaceuticals markets.
Technologies on display at Pall’s booth in Hall 6.0, E12-E15 include the Pall Stax™ single-use depth filter platform. The Pall Stax filter system helps reduce utility expense and costly labor time associated with the production of biopharmaceuticals, and it is the most flexible system for pre-filtration and clarification processes. It also eliminates cleaning validation requirements incurred by manufacturers with traditional plate and frame depth filtration systems. The platform can be anchored to the floor or placed on casters for easy mobility, and its compact vertical design (up to 6 feet/2 meters high) is scalable for size and performance to meet laboratory, pilot and process needs.
The Pall Stax system features interchangeable, single-use depth filter capsules housed in a stainless steel chassis that can be managed by one operator. The capsule sizes (small, medium and large) allow mix-and-match increases in filter area throughout the system’s modular design. The new platform uses Pall’s cellulose-based Seitz® high-performance depth filter media and its second-generation Supradisc™ II dual drainage plate modular design to encapsulate the media, ensuring high-performance filtration and overall process stability. Pall’s Supracap™ 60 and 100 capsule filters complement the new Stax system and allow process development from early R&D to full scale manufacturing with a highly predictable scale-up range of single-use capsules.
“Europe’s biotech industry is investing strongly in the future and funding large increases in research and development,” said Dr. Dirk Sievers, marketing manager of Pall GmbH Life Sciences. “The market’s long-term growth can only be secured through strong R&D activities and access to advanced technologies that will enable companies to tap into the biotech industry’s upward momentum in Europe. The technologies that we have available here today give European biotech and pharmaceutical companies the tools they need to succeed in this competitive market.”
Pall is also displaying a range of biotechnology and biopharmaceutical innovations from laboratory to process scale. These include:
Pall Allegro™ 1000 liter 3D biocontainers, which complement the 100, 200 and 500 liter sizes introduced last year and deliver a scalable product line that enhances the performance of Pall’s single-use systems for large-scale biotechnology and pharmaceutical manufacturing applications.
Pall Q and S HyperCel™ ion exchange sorbents, the most advanced chromatography sorbents for processing large amounts of protein during the capture and intermediate steps of purification.
PallSep™ Biotech PS50 oscillating membrane filter system for biotech applications requiring advanced tangential flow filtration for processing viscous or high-solids materials
Pall Fluorodyne® EX grade EDT filter, a 0.1 micron sterilizing grade filter designed for high throughput culture media applications that require secure mycoplasma control.
In addition to these technologies, Pall is highlighting five new initiatives that address current industry challenges, including:
Flexible solutions that feature Allegro single-use systems;
Process economics that address enhanced chromatography components and systems;
High-performance filtration providing single-use pilot- to production-scale clarification;
Total contamination control — the removal of the spectrum of potential risk organisms such as viruses, mycoplasmas, host cell proteins, DNA and bacteria;
Tangential Flow Filtration (TFF) systems and T-series cassettes that improve concentration and diafiltration of proteins and other molecules.
Editor's Notes: To schedule an interview at ACHEMA, contact Megan Maguire Kelly at 1-610-269-2100, ext. 225 or firstname.lastname@example.org.
About Pall Corporation
Pall Corporation is the global leader in the field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2008 were $2.6 billion. The company is headquartered in East Hills, New York, and has extensive operations around the world. For more information visit Pall at http://www.pall.com.
Media Contact: Megan Maguire Kelly
(610) 269-2100, ext. 225 email@example.com